Tag: Dr. Reddy’s

Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue

July 22, 2026 admin

Hyderabad-based generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit slumped 69% year-on-year (YoY) to ₹.435.6 crore in the June quarter amid lower sales of cancer drug lenalidomide and nearly ₹240 crore provision necessitated by recent quality issue around weight loss drug Semaglutide. Total revenue from operations stood at ₹8,099.8 crore (₹8,572.1 crore), showed its results…

Business

Dr. Reddy’s Q4 dips 86% on lower sales, multiple one offs to ₹221 crore

May 13, 2026 admin

On the SSA, the company said it recorded ₹453 crore as a reduction of revenue from sale of goods in its Global Generics Segment. | Photo Credit: The Hindu Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the…

Business

Dr. Reddy’s gets inspection report from USFDA for Srikakulam-based API plant

September 6, 2024 admin

Dr. Reddy’s Laboratories on Friday (September 6, 2024) said it has received the establishment inspection report (EIR) from the U.S. health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The U.S. Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection…

Business

Dr. Reddy’s biosimilar of Roche’s cancer drug gets EMA panel nod

July 29, 2024 admin

Dr. Reddy’s had previously received EU (Good manufacturing practice) GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending launch of Dr. Reddy’s Laboratories’ proposed biosimilar Rituximab candidate DRL_RI…

Business